scispace - formally typeset
M

Marc-Henri Stern

Researcher at Curie Institute

Publications -  196
Citations -  12240

Marc-Henri Stern is an academic researcher from Curie Institute. The author has contributed to research in topics: Gene & Breast cancer. The author has an hindex of 49, co-authored 168 publications receiving 9402 citations. Previous affiliations of Marc-Henri Stern include Necker-Enfants Malades Hospital & French Institute of Health and Medical Research.

Papers
More filters
Journal ArticleDOI

Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.

Katherine A Hoadley, +738 more
- 05 Apr 2018 - 
TL;DR: Molecular similarities among histologically or anatomically related cancer types provide a basis for focused pan-cancer analyses, such as pan-gastrointestinal, Pan-gynecological, pan-kidney, and pan-squamous cancers, and those related by stemness features, which may inform strategies for future therapeutic development.
Journal ArticleDOI

TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis

TL;DR: It is reported that inactivation of Tet2 in mouse perturbs both early and late steps of hematopoiesis including myeloid and lymphoid differentiation in a cell-autonomous manner, endows the cells with competitive advantage, and eventually leads to the development of malignancies.
Journal ArticleDOI

Genomic and Functional Approaches to Understanding Cancer Aneuploidy

Alison M. Taylor, +732 more
- 09 Apr 2018 - 
TL;DR: The genomic and phenotypic correlates of cancer aneuploidy are defined and genome engineering is applied to delete 3p in lung cells, causing decreased proliferation rescued in part by chromosome 3 duplication.
Journal ArticleDOI

Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma

A. Gordon Robertson, +173 more
- 14 Aug 2017 - 
TL;DR: Within D3-UM, EIF1AX- and SRSF2/SF3B1-mutant tumors have distinct somatic copy number alterations and DNA methylation profiles, providing insight into the biology of these low- versus intermediate-risk clinical mutation subtypes.
Journal ArticleDOI

Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation

TL;DR: The genomic signature defined predicted BRCA1/2 inactivation in BLCs with 100% sensitivity and 90% specificity (97% accuracy) may ease the challenge of selecting patients for genetic testing or recruitment to clinical trials of novel emerging therapies that target DNA repair deficiencies in cancer.